Targeting metabolic dysregulation for fibrosis therapy (original) (raw)

• Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028–1040 (2012).
  CAS PubMed PubMed Central Google Scholar
• Ley, B. & Collard, H. R. Epidemiology of idiopathic pulmonary fibrosis. Clin. Epidemiol. 5, 483–492 (2013).
  PubMed PubMed Central Google Scholar
• Conrad, N. et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391, 572–580 (2018).
  PubMed PubMed Central Google Scholar
• Furst, D. E., Fernandes, A. W., Iorga, S. R., Greth, W. & Bancroft, T. Epidemiology of systemic sclerosis in a large US managed care population. J. Rheumatol. 39, 784–786 (2012).
  PubMed Google Scholar
• Fleming, K. M., Aithal, G. P., Solaymani-Dodaran, M., Card, T. R. & West, J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study. J. Hepatol. 49, 732–738 (2008).
  PubMed Google Scholar
• Harris, R., Harman, D. J., Card, T. R., Aithal, G. P. & Guha, I. N. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol. Hepatol. 2, 288–297 (2017).
  PubMed Google Scholar
• van Blijderveen, J. C. et al. A population-based study on the prevalence and incidence of chronic kidney disease in the Netherlands. Int. Urol. Nephrol. 46, 583–592 (2014).
  PubMed Google Scholar
• Jha, V. et al. Chronic kidney disease: global dimension and perspectives. Lancet 382, 260–272 (2013).
  PubMed Google Scholar
• Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).
  PubMed Google Scholar
• Sayiner, M., Koenig, A., Henry, L. & Younossi, Z. M. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the united states and the rest of the world. Clin. Liver Dis. 20, 205–214 (2016).
  PubMed Google Scholar
• Shi, M. et al. Latent TGF-β structure and activation. Nature 474, 343–349 (2011).
  CAS PubMed PubMed Central Google Scholar
• Guo, Y., Xiao, L., Sun, L. & Liu, F. Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol. Res. 61, 337–346 (2012).
  CAS PubMed Google Scholar
• Attisano, L. & Wrana, J. L. Signal transduction by the TGF-beta superfamily. Science 296, 1646–1647 (2002).
  CAS PubMed Google Scholar
• Secker, G. A. et al. TGFbeta stimulated re-epithelialisation is regulated by CTGF and Ras/MEK/ERK signalling. Exp. Cell Res. 314, 131–142 (2008).
  CAS PubMed Google Scholar
• Xie, L. et al. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 6, 603–610 (2004).
  CAS PubMed PubMed Central Google Scholar
• Hayashida, T., Decaestecker, M. & Schnaper, H. W. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 17, 1576–1578 (2003).
  CAS PubMed Google Scholar
• Li, X., Meng, Y., Yang, X. S., Mi, L. F. & Cai, S. X. ACEI attenuates the progression of CCl4-induced rat hepatic fibrogenesis by inhibiting TGF-beta1, PDGF-BB, NF-kappaB and MMP-2,9. World J. Gastroenterol. 11, 4807–4811 (2005).
  CAS PubMed PubMed Central Google Scholar
• Lan, R. et al. PTEN loss defines a TGF-β-induced tubule phenotype of failed differentiation and JNK signaling during renal fibrosis. Am. J. Physiol. Ren. Physiol. 302, F1210–F1223 (2012).
  CAS Google Scholar
• Kattla, J. J., Carew, R. M., Heljic, M., Godson, C. & Brazil, D. P. Protein kinase B/Akt activity is involved in renal TGF-beta1-driven epithelial-mesenchymal transition in vitro and in vivo. Am. J. Physiol Ren. Physiol. 295, F215–F225 (2008).
  CAS Google Scholar
• Ono, K., Ohtomo, T., Ninomiya-Tsuji, J. & Tsuchiya, M. A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-beta. Biochem. Biophys. Res. Commun. 307, 332–337 (2003).
  CAS PubMed Google Scholar
• Gu, J. et al. Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts. Exp. Cell Res. 318, 2105–2115 (2012).
  CAS PubMed Google Scholar
• Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577–584 (2003).
  CAS PubMed Google Scholar
• Philips, G. M. et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLOS ONE 6, e23943 (2011).
  CAS PubMed PubMed Central Google Scholar
• Shirasaki, T. et al. Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway. Hepatology 60, 1519–1530 (2014).
  CAS PubMed Google Scholar
• Djudjaj, S. et al. Notch-3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury. J. Pathol. 228, 286–299 (2012).
  CAS PubMed Google Scholar
• Matsuno, Y., Coelho, A. L., Jarai, G., Westwick, J. & Hogaboam, C. M. Notch signaling mediates TGF-β1-induced epithelial-mesenchymal transition through the induction of Snai1. Int. J. Biochem. Cell Biol. 44, 776–789 (2012).
  CAS PubMed Google Scholar
• Stratton, R. et al. Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J. 16, 1949–1951 (2002).
  CAS PubMed Google Scholar
• Armendariz-Borunda, J., Katayama, K. & Seyer, J. M. Transcriptional mechanisms of type I collagen gene expression are differentially regulated by interleukin-1 beta, tumor necrosis factor alpha, and transforming growth factor beta in Ito cells. J. Biol. Chem. 267, 14316–14321 (1992).
  CAS PubMed Google Scholar
• Akhmetshina, A. et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat. Commun. 3, 735 (2012).
  PubMed Google Scholar
• Guo, X. & Wang, X. F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 19, 71–88 (2009).
  CAS PubMed Google Scholar
• Varga, J. & Jimenez, S. A. Stimulation of normal human fibroblast collagen production and processing by transforming growth factor-beta. Biochem. Biophys. Res. Commun. 138, 974–980 (1986).
  CAS PubMed Google Scholar
• Hoff, C. R., Perkins, D. R. & Davidson, J. M. Elastin gene expression is upregulated during pulmonary fibrosis. Connect. Tissue Res. 40, 145–153 (1999).
  CAS PubMed Google Scholar
• Bouzeghrane, F., Reinhardt, D. P., Reudelhuber, T. L. & Thibault, G. Enhanced expression of fibrillin-1, a constituent of the myocardial extracellular matrix in fibrosis. Am. J. Physiol. Heart Circ. Physiol. 289, H982–H991 (2005).
  CAS PubMed Google Scholar
• Muro, A. F. et al. An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 177, 638–645 (2008).
  CAS PubMed Google Scholar
• Van Berlo, J. H. et al. A-type lamins are essential for TGF-beta1 induced PP2A to dephosphorylate transcription factors. Hum. Mol. Genet. 14, 2839–2849 (2005).
  PubMed Google Scholar
• Bensadoun, E. S., Burke, A. K., Hogg, J. C. & Roberts, C. R. Proteoglycan deposition in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 154, 1819–1828 (1996).
  CAS PubMed Google Scholar
• Klingberg, F., Hinz, B. & White, E. S. The myofibroblast matrix: implications for tissue repair and fibrosis. J. Pathol. 229, 298–309 (2013).
  CAS PubMed PubMed Central Google Scholar
• Schlingensiepen, R. et al. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 15, 94–104 (2005).
  CAS PubMed Google Scholar
• Schlingensiepen, K. H. et al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 102, 1193–1200 (2011).
  CAS PubMed Google Scholar
• Schlingensiepen, K. H. et al. Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17, 129–139 (2006).
  CAS PubMed Google Scholar
• Santiago, B. et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J. Invest. Dermatol. 125, 450–455 (2005).
  CAS PubMed Google Scholar
• Laping, N. J. et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol. Pharmacol. 62, 58–64 (2002).
  CAS PubMed Google Scholar
• Zhou, C. et al. A targeted transforming growth factor-beta (TGF-β) blocker, TTB, inhibits tumor growth and metastasis. Oncotarget 9, 23102–23113 (2018).
  PubMed PubMed Central Google Scholar
• Nam, J. S. et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68, 3835–3843 (2008).
  CAS PubMed PubMed Central Google Scholar
• Rodon, J. et al. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin. Cancer Res. 21, 553–560 (2015).
  CAS PubMed Google Scholar
• Daniels, C. E. et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 114, 1308–1316 (2004).
  CAS PubMed PubMed Central Google Scholar
• Akhurst, R. J. & Hata, A. Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790–811 (2012).
  CAS PubMed PubMed Central Google Scholar
• Rangarajan, S. et al. Novel mechanisms for the antifibrotic action of nintedanib. Am. J. Respir. Cell Mol. Biol. 54, 51–59 (2016).
  CAS PubMed PubMed Central Google Scholar
• Sato, S. et al. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir. Res. 18, 172 (2017).
  PubMed PubMed Central Google Scholar
• Iyer, S. N., Gurujeyalakshmi, G. & Giri, S. N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291, 367–373 (1999).
  CAS PubMed Google Scholar
• Oku, H., Nakazato, H., Horikawa, T., Tsuruta, Y. & Suzuki, R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol. 446, 167–176 (2002).
  CAS PubMed Google Scholar
• Meng, X. M. et al. Disruption of Smad4 impairs TGF-β/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int. 81, 266–279 (2012).
  CAS PubMed Google Scholar
• O’Kane, S. & Ferguson, M. W. Transforming growth factor βs and wound healing. Int. J. Biochem. Cell Biol. 29, 63–78 (1997).
  CAS PubMed Google Scholar
• Principe, D. R. et al. TGF-β: duality of function between tumor prevention and carcinogenesis. J. Natl Cancer Inst. 106, djt369 (2014).
  PubMed PubMed Central Google Scholar
• Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A. K. & Flavell, R. A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24, 99–146 (2006).
  CAS PubMed Google Scholar
• Jiang, L. et al. Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition. Oncogene 34, 3908–3916 (2015).
  CAS PubMed Google Scholar
• Kang, Y. P. et al. Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. J. Proteome Res. 15, 1717–1724 (2016).
  CAS PubMed Google Scholar
• Win, T. et al. Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients. Eur. J. Nucl. Med. Mol. Imaging. 41, 337–342 (2014).
  PubMed Google Scholar
• Calvier, L. et al. PPARγ Links BMP2 and TGFβ1 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism. Cell Metab. 25, 1118–1134.e1117 (2017).
  CAS PubMed Google Scholar
• Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177–185 (2006).
  PubMed Google Scholar
• Ueno, M. et al. Hypoxia-inducible factor-1α mediates TGF-β-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 300, L740–L752 (2011).
  CAS PubMed Google Scholar
• Goodwin, J. et al. Targeting hypoxia-inducible factor-1α/pyruvate dehydrogenase kinase 1 axis by dichloroacetate suppresses bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 58, 216–231 (2018).
  CAS PubMed PubMed Central Google Scholar
• Wilhelm, K. et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature 529, 216–220 (2016).
  CAS PubMed PubMed Central Google Scholar
• Ha, H., Yu, M. R. & Lee, H. B. High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int. 59, 463–470 (2001).
  CAS PubMed Google Scholar
• Cheng, X. et al. Both ERK/MAPK and TGF-Beta/Smad signaling pathways play a role in the kidney fibrosis of diabetic mice accelerated by blood glucose fluctuation. J. Diabetes Res. 2013, 463740 (2013).
  PubMed PubMed Central Google Scholar
• Singh, V. P., Baker, K. M. & Kumar, R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am. J. Physiol. Heart Circ. Physiol. 294, H1675–H1684 (2008).
  CAS PubMed Google Scholar
• Xie, N. et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am. J. Respir. Crit. Care Med. 192, 1462–1474 (2015). This study reveals increased glycolysis as an important promoter of lung myofibroblast differentiation. Further, it shows that inhibition of the glycolytic enzyme PFKFB3 by genetic and pharmacological means decreased lung fibrosis in mice.
  CAS PubMed PubMed Central Google Scholar
• Lemons, J. M. et al. Quiescent fibroblasts exhibit high metabolic activity. PLOS Biol. 8, e1000514 (2010).
  PubMed PubMed Central Google Scholar
• Kottmann, R. M. et al. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-β. Am. J. Respir. Crit. Care Med. 186, 740–751 (2012).
  CAS PubMed PubMed Central Google Scholar
• Hoyles, R. K. et al. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor. Am. J. Respir. Crit. Care Med. 183, 249–261 (2011).
  CAS PubMed Google Scholar
• Phillips, R. J. et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 114, 438–446 (2004).
  CAS PubMed PubMed Central Google Scholar
• Kim, K. K. et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA 103, 13180–13185 (2006).
  CAS PubMed PubMed Central Google Scholar
• McKleroy, W., Lee, T. H. & Atabai, K. Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 304, L709–L721 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kuhn, C. et al. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am. Rev. Respir. Dis. 140, 1693–1703 (1989).
  PubMed Google Scholar
• Basak, T. et al. Comprehensive characterization of glycosylation and hydroxylation of basement membrane collagen iv by high-resolution mass spectrometry. J. Proteome Res. 15, 245–258 (2016).
  CAS PubMed Google Scholar
• Di Lullo, G. A., Sweeney, S. M., Korkko, J., Ala-Kokko, L. & San Antonio, J. D. Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen. J. Biol. Chem. 277, 4223–4231 (2002).
  PubMed Google Scholar
• Cheng, T. et al. Lysyl oxidase promotes bleomycin-induced lung fibrosis through modulating inflammation. J. Mol. Cell Biol. 6, 506–515 (2014).
  CAS PubMed Google Scholar
• López, B. et al. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am. J. Physiol. Heart Circ. Physiol. 299, H1–H9 (2010).
  PubMed Google Scholar
• de Paz-Lugo, P., Lupiáñez, J. A. & Meléndez-Hevia, E. High glycine concentration increases collagen synthesis by articular chondrocytes in vitro: acute glycine deficiency could be an important cause of osteoarthritis. Amino Acids 50, 1357–1365 (2018).
  PubMed PubMed Central Google Scholar
• Im, M. J., Freshwater, M. F. & Hoopes, J. E. Enzyme activities in granulation tissue: energy for collagen synthesis. J. Surg. Res. 20, 121–125 (1976).
  CAS PubMed Google Scholar
• Keppler, D. O. & Hübner, G. Liver injury induced by 2-deoxy-D-galactose. Exp. Mol. Pathol. 19, 365–377 (1973).
  CAS PubMed Google Scholar
• Schietke, R. et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J. Biol. Chem. 285, 6658–6669 (2010).
  CAS PubMed Google Scholar
• Iyer, N. V. et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12, 149–162 (1998).
  CAS PubMed PubMed Central Google Scholar
• Morell, B. & Froesch, E. R. Fibroblasts as an experimental tool in metabolic and hormone studies. I. Growth and glucose metabolism of fibroblasts in culture. Eur. J. Clin. Invest. 3, 112–118 (1973).
  CAS PubMed Google Scholar
• Kruse, N. J. & Bornstein, P. The metabolic requirements for transcellular movement and secretion of collagen. J. Biol. Chem. 250, 4841–4847 (1975).
  CAS PubMed Google Scholar
• Vincent, A. S. et al. Human skin keloid fibroblasts display bioenergetics of cancer cells. J. Invest. Dermatol. 128, 702–709 (2008).
  CAS PubMed Google Scholar
• Nishikawa, T. et al. A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. J. Hepatol. 60, 1203–1211 (2014).
  CAS PubMed PubMed Central Google Scholar
• Ding, H. et al. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis. Am. J. Physiol. Ren. Physiol. 313, F561–F575 (2017). This study shows the role of aerobic glycolysis in renal fibroblast activation and the therapeutic effect of pharmacological reduction of the phosphorylation of PKM2 (a rate-limiting glycolytic enzyme) to decrease mouse renal fibrosis.
  CAS Google Scholar
• Álvarez, D. et al. IPF lung fibroblasts have a senescent phenotype. Am. J. Physiol. Lung Cell Mol. Physiol. 313, L1164–L1173 (2017).
  PubMed PubMed Central Google Scholar
• Zhao, Y. D. et al. Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study. BMJ Open Respir. Res. 4, e000183 (2017). This study performed mass spectrometry-based metabolomic profiling of lung tissue from patients with and without IPF and identified disruption of 108 metabolites indicative of altered glycolysis, mitochondrial β-oxidation and citric acid cycle, bile acid, haem and amino acid metabolism.
  PubMed PubMed Central Google Scholar
• Schultz, G. S., Davidson, J. M., Kirsner, R. S., Bornstein, P. & Herman, I. M. Dynamic reciprocity in the wound microenvironment. Wound Repair Regen. 19, 134–148 (2011).
  PubMed PubMed Central Google Scholar
• Holmbeck, K. et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81–92 (1999).
  CAS PubMed Google Scholar
• Duffield, J. S. et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115, 56–65 (2005).
  CAS PubMed PubMed Central Google Scholar
• Lim, D. H. et al. Reduced peribronchial fibrosis in allergen-challenged MMP-9-deficient mice. Am. J. Physiol. Lung Cell Mol. Physiol. 291, L265–L271 (2006).
  CAS PubMed Google Scholar
• Li, A. H., Liu, P. P., Villarreal, F. J. & Garcia, R. A. Dynamic changes in myocardial matrix and relevance to disease: translational perspectives. Circ. Res. 114, 916–927 (2014).
  CAS PubMed Google Scholar
• Yamashita, C. M. et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am. J. Pathol. 179, 1733–1745 (2011).
  CAS PubMed PubMed Central Google Scholar
• García-Prieto, E. et al. Resistance to bleomycin-induced lung fibrosis in MMP-8 deficient mice is mediated by interleukin-10. PLOS ONE 5, e13242 (2010).
  PubMed PubMed Central Google Scholar
• Ghosh, A. K. & Vaughan, D. E. PAI-1 in tissue fibrosis. J. Cell Physiol. 227, 493–507 (2012).
  CAS PubMed PubMed Central Google Scholar
• Tuan, T. L. et al. Increased plasminogen activator inhibitor-1 in keloid fibroblasts may account for their elevated collagen accumulation in fibrin gel cultures. Am. J. Pathol. 162, 1579–1589 (2003).
  CAS PubMed PubMed Central Google Scholar
• Senoo, T. et al. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 65, 334–340 (2010).
  PubMed Google Scholar
• Brew, K. & Nagase, H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim. Biophys. Acta 1803, 55–71 (2010).
  CAS PubMed PubMed Central Google Scholar
• Aoki, M. et al. siRNA knockdown of tissue inhibitor of metalloproteinase-1 in keloid fibroblasts leads to degradation of collagen type I. J. Invest. Dermatol. 134, 818–826 (2014).
  CAS PubMed Google Scholar
• McLennan, S. V., Wang, X. Y., Moreno, V., Yue, D. K. & Twigg, S. M. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145, 5646–5655 (2004).
  CAS PubMed Google Scholar
• Roten, L. et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J. Mol. Cell. Cardiol. 32, 109–120 (2000).
  CAS PubMed Google Scholar
• Kassiri, Z. et al. Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J. Biol. Chem. 284, 29893–29904 (2009).
  CAS PubMed PubMed Central Google Scholar
• Leco, K. J. et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J. Clin. Invest. 108, 817–829 (2001).
  CAS PubMed PubMed Central Google Scholar
• Heymans, S. et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112, 1136–1144 (2005).
  CAS PubMed Google Scholar
• Wang, H. et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell Biosci. 1, 14 (2011).
  CAS PubMed PubMed Central Google Scholar
• Madsen, D. H. et al. M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway. J. Cell Biol. 202, 951–966 (2013).
  CAS PubMed PubMed Central Google Scholar
• Madsen, D. H. et al. Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation. J. Biol. Chem. 282, 27037–27045 (2007).
  CAS PubMed Google Scholar
• Abraham, L. C., Dice, J. F., Lee, K. & Kaplan, D. L. Phagocytosis and remodeling of collagen matrices. Exp. Cell Res. 313, 1045–1055 (2007).
  CAS PubMed PubMed Central Google Scholar
• Ma, R. H., Tsai, C. C. & Shieh, T. Y. Increased lysyl oxidase activity in fibroblasts cultured from oral submucous fibrosis associated with betel nut chewing in Taiwan. J. Oral Pathol. Med. 24, 407–412 (1995).
  CAS PubMed Google Scholar
• Harvey, W., Scutt, A., Meghji, S. & Canniff, J. P. Stimulation of human buccal mucosa fibroblasts in vitro by betel-nut alkaloids. Arch. Oral Biol. 31, 45–49 (1986).
  CAS PubMed Google Scholar
• Lee, H., Overall, C. M., McCulloch, C. A. & Sodek, J. A critical role for the membrane-type 1 matrix metalloproteinase in collagen phagocytosis. Mol Biol Cell. 17, 4812–4826 (2006).
  CAS PubMed PubMed Central Google Scholar
• Zigrino, P. et al. Fibroblast-derived MMP-14 regulates collagen homeostasis in adult skin. J. Invest. Dermatol. 136, 1575–1583 (2016).
  CAS PubMed PubMed Central Google Scholar
• Martin, G. et al. The human fatty acid transport protein-1 (SLC27A1; FATP-1) cDNA and gene: organization, chromosomal localization, and expression. Genomics 66, 296–304 (2000).
  CAS PubMed Google Scholar
• Ibrahimi, A. et al. Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Proc. Natl Acad. Sci. USA 93, 2646–2651 (1996).
  CAS PubMed PubMed Central Google Scholar
• Kang, H. M. et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 21, 37–46 (2015). This study reveals that downregulation of fatty acid oxidation and increased intracellular lipid deposition are characteristic of renal fibrosis in mice and humans. Furthermore, it finds lack of renal fibrosis when fatty acid metabolism is normalized by genetic and pharmacological approaches.
  CAS PubMed Google Scholar
• Proctor, G. et al. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55, 2502–2509 (2006).
  CAS PubMed Google Scholar
• Nilsson, L. et al. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18, 1679–1685 (1998).
  CAS PubMed Google Scholar
• Rangarajan, S. et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat. Med. 24, 1121–1127 (2018). This study reveals the role of AMPK as a regulator of mitochondrial biogenesis and normal apoptosis of lung myofibroblasts. The findings support the use of AMPK activators, such as metformin, in decreasing fibrosis.
  CAS PubMed PubMed Central Google Scholar
• Lakshmi, S. P., Reddy, A. T. & Reddy, R. C. Transforming growth factor β suppresses peroxisome proliferator-activated receptor γ expression via both SMAD binding and novel TGF-β inhibitory elements. Biochem. J. 474, 1531–1546 (2017).
  CAS PubMed Google Scholar
• Qian, J., Niu, M., Zhai, X., Zhou, Q. & Zhou, Y. β-Catenin pathway is required for TGF-β1 inhibition of PPARγ expression in cultured hepatic stellate cells. Pharmacol. Res. 66, 219–225 (2012).
  CAS PubMed Google Scholar
• Zheng, F. et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am. J. Physiol. Ren. Physiol. 282, F639–F648 (2002).
  CAS Google Scholar
• Wei, J. et al. PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLOS ONE 5, e13778 (2010).
  PubMed PubMed Central Google Scholar
• Zhao, X. et al. Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis. Nat. Metabolism 1, 147–157 (2019). This study reveals the presence of decreased fatty acid oxidation in skin fibrosis. Furthermore, activation of fatty acid oxidation, via PPAR signalling, decreased transcriptional regulation and promoted degradation of ECM proteins.
  Google Scholar
• Chen, H. et al. Macrophage peroxisome proliferator-activated receptor γ deficiency delays skin wound healing through impairing apoptotic cell clearance in mice. Cell Death Dis. 6, e1597 (2015).
  CAS PubMed PubMed Central Google Scholar
• Lauber, K. et al. Milk fat globule-EGF factor 8 mediates the enhancement of apoptotic cell clearance by glucocorticoids. Cell Death Differ. 20, 1230–1240 (2013).
  CAS PubMed PubMed Central Google Scholar
• Borregaard, N. & Herlin, T. Energy metabolism of human neutrophils during phagocytosis. J. Clin. Invest. 70, 550–557 (1982).
  CAS PubMed PubMed Central Google Scholar
• Yamauchi, T. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288–1295 (2002).
  CAS PubMed Google Scholar
• Kalhan, S. C. et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 60, 404–413 (2011).
  CAS PubMed Google Scholar
• Constantinou, M. A., Theocharis, S. E. & Mikros, E. Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats. Toxicol. Appl. Pharmacol. 218, 11–19 (2007).
  CAS PubMed Google Scholar
• Pena, M. J. et al. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabet. Med. 31, 1138–1147 (2014).
  CAS PubMed Google Scholar
• Yu, B. et al. Serum metabolomic profiling and incident ckd among african americans. Clin. J. Am. Soc. Nephrol. 9, 1410–1417 (2014).
  CAS PubMed PubMed Central Google Scholar
• Niewczas, M. A. et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int. 85, 1214–1224 (2014).
  CAS PubMed PubMed Central Google Scholar
• Gou, X. et al. Urinary metabonomics characterization of liver fibrosis induced by CCl4 in rats and intervention effects of Xia Yu Xue decoction. J. Pharm. Biomed. Anal. 74, 62–65 (2013).
  CAS PubMed Google Scholar
• Bradford, B. U. et al. Metabolomic profiling of a modified alcohol liquid diet model for liver injury in the mouse uncovers new markers of disease. Toxicol. Appl. Pharmacol. 232, 236–243 (2008).
  CAS PubMed PubMed Central Google Scholar
• Posada-Ayala, M. et al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int. 85, 103–111 (2014).
  CAS PubMed Google Scholar
• Tokushige, K. et al. Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease. J. Gastroenterol. 48, 1392–1400 (2013).
  CAS PubMed PubMed Central Google Scholar
• Schoors, S. et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 19, 37–48 (2014).
  CAS PubMed Google Scholar
• Tang, M. et al. High glucose promotes the production of collagen types I and III by cardiac fibroblasts through a pathway dependent on extracellular-signal-regulated kinase 1/2. Mol. Cell Biochem. 301, 109–114 (2007).
  CAS PubMed Google Scholar
• Westermann, D. et al. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56, 641–646 (2007).
  CAS PubMed Google Scholar
• Jia, Y. et al. Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells. Exp. Mol. Med. 50, 56 (2018).
  PubMed Central Google Scholar
• Febbraio, M., Hajjar, D. P. & Silverstein, R. L. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108, 785–791 (2001).
  CAS PubMed PubMed Central Google Scholar
• Souza, A. C. et al. Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation. Kidney Int. 89, 809–822 (2016).
  CAS PubMed PubMed Central Google Scholar
• Gagnon, L. et al. A newly discovered antifibrotic pathway regulated by two fatty acid receptors: GPR40 and GPR84. Am. J. Pathol. 188, 1132–1148 (2018). This study identifies the therapeutic potential of targeting the fatty acid receptors GPR40 and GPR84 using a synthetic fatty acid analogue, 3-pentylbenzeneacetic acid sodium salt (PBI-4050), to reduce fibrosis.
  CAS PubMed Google Scholar
• Jung, M. Y. et al. Fatty acid synthase is required for profibrotic TGF-β signaling. FASEB J. 32, 3803–3815 (2018).
  CAS PubMed PubMed Central Google Scholar
• Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147–1159.e1145 (2016).
  CAS PubMed Google Scholar
• Avouac, J. et al. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann. Rheum. Dis. 76, 1931–1940 (2017).
  CAS PubMed Google Scholar
• Zhang, Y. et al. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats. Cytokine 75, 127–135 (2015).
  CAS PubMed Google Scholar
• Aleshin, S., Grabeklis, S., Hanck, T., Sergeeva, M. & Reiser, G. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels. Mol. Pharmacol. 76, 414–424 (2009).
  CAS PubMed Google Scholar
• Irrcher, I., Walkinshaw, D. R., Sheehan, T. E. & Hood, D. A. Thyroid hormone (T3) rapidly activates p38 and AMPK in skeletal muscle in vivo. J. Appl. Physiol. (1985). 104, 178–185 (2008).
  CAS Google Scholar
• Cao, X., Kambe, F., Moeller, L. C., Refetoff, S. & Seo, H. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol. Endocrinol. 19, 102–112 (2005).
  CAS PubMed Google Scholar
• Adams, A. C. et al. Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner. J. Biol. Chem. 285, 14078–14082 (2010).
  CAS PubMed PubMed Central Google Scholar
• Kim, D. et al. Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis. Clin. Gastroenterol. Hepatol. 16, 123–131.e121 (2018).
  CAS PubMed Google Scholar
• Yu, G. et al. Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nat. Med. 24, 39–49 (2018). This study reveals the role of thyroid hormone activity in supporting mitochondrial biogenesis and viability of alveolar epithelial cells. Administration of thyroid hormone decreased lung fibrosis in mice.
  CAS PubMed Google Scholar
• Arena, G. et al. PINK1 protects against cell death induced by mitochondrial depolarization, by phosphorylating Bcl-xL and impairing its pro-apoptotic cleavage. Cell Death Differ. 20, 920–930 (2013).
  CAS PubMed PubMed Central Google Scholar
• Alonso-Merino, E. et al. Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses. Proc. Natl Acad. Sci. USA 113, E3451–E3460 (2016).
  CAS PubMed PubMed Central Google Scholar
• Lu, X. et al. Thyroid hormone inhibits TGFβ1 induced renal tubular epithelial to mesenchymal transition by increasing miR34a expression. Cell Signal. 25, 1949–1954 (2013).
  CAS PubMed Google Scholar
• Kahn, C. R. et al. The insulin receptor and its substrate: molecular determinants of early events in insulin action. Recent Prog. Horm. Res. 48, 291–339 (1993).
  CAS PubMed Google Scholar
• LeRoith, D., Werner, H., Beitner-Johnson, D. & Roberts, C. T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16, 143–163 (1995).
  CAS PubMed Google Scholar
• Marra, F. et al. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor’s actions on hepatic stellate cells. Gastroenterology 112, 1297–1306 (1997).
  CAS PubMed Google Scholar
• Davis, B. H., Chen, A. & Beno, D. W. Raf and mitogen-activated protein kinase regulate stellate cell collagen gene expression. J. Biol. Chem. 271, 11039–11042 (1996).
  CAS PubMed Google Scholar
• Svegliati-Baroni, G. et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 29, 1743–1751 (1999).
  CAS PubMed Google Scholar
• Jung, U. J., Lee, M. K., Jeong, K. S. & Choi, M. S. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J. Nutr. 134, 2499–2503 (2004).
  CAS PubMed Google Scholar
• Zhang, Z., Liu, H. & Liu, J. Akt activation: a potential strategy to ameliorate insulin resistance. Diabetes Res. Clin. Pract. S0168-8227, 30315–30317 (2017).
  Google Scholar
• Garcia, F. A. et al. Pentoxifylline decreases glycemia levels and TNF-alpha, iNOS and COX-2 expressions in diabetic rat pancreas. Springerplus 3, 283 (2014).
  PubMed PubMed Central Google Scholar
• Jung, U. J., Lee, M. K., Park, Y. B., Kang, M. A. & Choi, M. S. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int. J. Biochem. Cell Biol. 38, 1134–1145 (2006).
  CAS PubMed Google Scholar
• Spagnolo, P. et al. Metformin does not affect clinically relevant outcomes in patients with idiopathic pulmonary fibrosis. Respiration 96, 314–322 (2018).
  CAS PubMed Google Scholar
• Gingras, A. A. et al. Long-chain omega-3 fatty acids regulate bovine whole-body protein metabolism by promoting muscle insulin signalling to the Akt-mTOR-S6K1 pathway and insulin sensitivity. J. Physiol. 579, 269–284 (2007).
  CAS PubMed Google Scholar
• Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292, 1728–1731 (2001).
  CAS PubMed Google Scholar
• Zeng, Z. et al. Omega-3 Polyunsaturated fatty acids attenuate fibroblast activation and kidney fibrosis involving MTORC2 signaling suppression. Sci. Rep. 7, 46146 (2017).
  CAS PubMed PubMed Central Google Scholar
• Zabel, P., Schade, F. U. & Schlaak, M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187, 447–463 (1993).
  CAS PubMed Google Scholar
• Hotamisligil, G. S. Mechanisms of TNF-alpha-induced insulin resistance. Exp. Clin. Endocrinol. Diabetes 107, 119–125 (1999).
  CAS PubMed Google Scholar
• Wettstein, G. et al. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. Hepatol. Commun. 1, 524–537 (2017). This study reveals the therapeutic effects of IVA337, a pan-PPAR agonist that transcriptionally upregulates β-oxidation and fatty acid desaturation, in normalizing metabolic dysregulation and fibrosis associated with NASH.
  CAS PubMed PubMed Central Google Scholar
• Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956–965 (2015).
  CAS PubMed Google Scholar
• Verbeke, L. et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci. Rep. 6, 33453 (2016).
  CAS PubMed PubMed Central Google Scholar
• Fiorucci, S. et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther. 314, 584–595 (2005).
  CAS PubMed Google Scholar
• Comeglio, P. et al. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis. J. Steroid Biochem. Mol. Biol. 168, 26–37 (2017).
  CAS PubMed Google Scholar
• De Magalhaes Filho, C. D., Downes, M. & Evans, R. Bile acid analog intercepts liver fibrosis. Cell 166, 789 (2016).
  PubMed Google Scholar
• Clark, J. M., Brancati, F. L. & Diehl, A. M. Nonalcoholic fatty liver disease. Gastroenterology 122, 1649–1657 (2002).
  PubMed Google Scholar
• Bruno, S. et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330, 932 (2005).
  PubMed PubMed Central Google Scholar
• Yang, J. D. et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 59, 1406–1414 (2014).
  CAS PubMed Google Scholar
• Peters-Golden, M. et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. 165, 229–235 (2002).
  PubMed Google Scholar
• Devchand, P. R. et al. The PPARα–leukotriene B4 pathway to inflammation control. Nature 384, 39–43 (1996).
  CAS PubMed Google Scholar
• Wilborn, J. et al. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest. 97, 1827–1836 (1996).
  CAS PubMed PubMed Central Google Scholar
• Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006).
  CAS PubMed Google Scholar
• Subramanian, A., Narayan, R. & Corsello, S. A NEXT generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437–1452.e17 (2017).
  CAS PubMed PubMed Central Google Scholar
• Vidović, D., Koleti, A. & Schürer, S. C. Large-scale integration of small molecule-induced genome-wide transcriptional responses, kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action. Front. Genet. 5, 342 (2014).
  PubMed PubMed Central Google Scholar
• Karatzas, E., Bourdakou, M. M., Kolios, G. & Spyrou, G. M. Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score. Sci. Rep. 7, 12569 (2017).
  CAS PubMed PubMed Central Google Scholar
• Li, L. et al. Novel therapeutics identification for fibrosis in renal allograft using integrative informatics approach. Sci. Rep. 7, 39487 (2017).
  CAS PubMed PubMed Central Google Scholar
• Stefanovic, B. & Stefanovic, L. Screening for antifibrotic compounds using high throughput system based on fluorescence polarization. Biology 3, 281–294 (2014).
  CAS Google Scholar
• Zheng, B. et al. Predicting in vivo anti-hepatofibrotic drug efficacy based on in vitro high-content analysis. PLOS ONE 6, e26230 (2011).
  CAS PubMed PubMed Central Google Scholar
• Xu, Q., Norman, J. T., Shrivastav, S., Lucio-Cazana, J. & Kopp, J. B. In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of antifibrotic agents. Am. J. Physiol. Ren. Physiol. 293, F631–F640 (2007).
  CAS Google Scholar
• Leite, S. B. et al. Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro. Biomaterials 78, 1–10 (2016).
  CAS PubMed Google Scholar
• Rodansky, E. S., Johnson, L. A., Huang, S., Spence, J. R. & Higgins, P. D. Intestinal organoids: a model of intestinal fibrosis for evaluating anti-fibrotic drugs. Exp. Mol. Pathol. 98, 346–351 (2015).
  CAS PubMed PubMed Central Google Scholar
• Asmani, M. et al. Fibrotic microtissue array to predict anti-fibrosis drug efficacy. Nat. Commun. 9, 2066 (2018).
  PubMed PubMed Central Google Scholar
• Kodack, D. P. et al. Primary patient-derived cancer cells and their potential for personalized cancer patient care. Cell Rep. 21, 3298–3309 (2017).
  CAS PubMed PubMed Central Google Scholar
• Korfhagen, T. R. et al. Respiratory epithelial cell expression of human transforming growth factor-alpha induces lung fibrosis in transgenic mice. J. Clin. Invest. 93, 1691–1699 (1994).
  CAS PubMed PubMed Central Google Scholar
• Zhu, Z. et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103, 779–788 (1999).
  CAS PubMed PubMed Central Google Scholar
• Smith, R. E. et al. A role for C-C chemokines in fibrotic lung disease. J. Leukoc. Biol. 57, 782–787 (1995).
  CAS PubMed Google Scholar
• Chevalier, R. L., Thornhill, B. A. & Chang, A. Y. Unilateral ureteral obstruction in neonatal rats leads to renal insufficiency in adulthood. Kidney Int. 58, 1987–1995 (2000).
  CAS PubMed Google Scholar
• Chevalier, R. L., Forbes, M. S. & Thornhill, B. A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 75, 1145–1152 (2009).
  PubMed Google Scholar
• Degryse, A. L. & Lawson, W. E. Progress toward improving animal models for idiopathic pulmonary fibrosis. Am. J. Med. Sci. 341, 444–449 (2011).
  PubMed PubMed Central Google Scholar
• Schrier, D. J., Kunkel, R. G. & Phan, S. H. The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am. Rev. Respir. Dis. 127, 63–66 (1983).
  CAS PubMed Google Scholar
• Harrison, J. H. & Lazo, J. S. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J. Pharmacol. Exp. Ther. 243, 1185–1194 (1987).
  CAS PubMed Google Scholar
• Yang, L. et al. Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics. Dig. Dis. Sci. 56, 3305–3315 (2011).
  CAS PubMed PubMed Central Google Scholar
• Ho, J. E. et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 60, 1249–1256 (2012).
  CAS PubMed PubMed Central Google Scholar
• Liu, T., Wang, X., Karsdal, M. A., Leeming, D. J. & Genovese, F. Molecular serum markers of liver fibrosis. Biomark. Insights 7, 105–117 (2012).
  PubMed PubMed Central Google Scholar
• Jenkins, R. G. et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir. Med. 3, 462–472 (2015). This prospective, multicentre, observational cohort study (PROFILE) shows the presence of increased levels of MMP cleaved protein fragments in the serum of patients with IPF. This study reveals the potential utility of collagen degradation proteins as theragnostic biomarkers for lung fibrosis.
  CAS PubMed Google Scholar
• Papasotiriou, M. et al. Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases. Nephrol. Dial. Transplant. 30, 1112–1121 (2015).
  CAS PubMed Google Scholar
• Togao, O. et al. Assessment of renal fibrosis with diffusion-weighted MR imaging: study with murine model of unilateral ureteral obstruction. Radiology 255, 772–780 (_2_010).
  PubMed PubMed Central Google Scholar
• Désogère, P. et al. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci. Transl Med. 9, 384 (2017).
  Google Scholar
• Goldstein, N. S., Hastah, F., Galan, M. V. & Gordon, S. C. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. Am. J. Clin. Pathol. 123, 382–387 (2005).
  PubMed Google Scholar
• Dyvorne, H. A. et al. Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection. Liver Int. 36, 659–666 (2016).
  CAS PubMed PubMed Central Google Scholar
• Gallagher, F. A. et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 453, 940–943 (2008).
  CAS PubMed Google Scholar
• Jadvar, H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J. Nucl. Med. 52, 81–89 (2011).
  PubMed Google Scholar
• Fuchs, B. C. et al. Molecular MRI of collagen to diagnose and stage liver fibrosis. J. Hepatol. 59, 992–998 (2013).
  CAS PubMed PubMed Central Google Scholar
• Martin, P. Wound healing — aiming for perfect skin regeneration. Science 276, 75–81 (1997).
  CAS PubMed Google Scholar
• Stapor, P., Wang, X., Goveia, J., Moens, S. & Carmeliet, P. Angiogenesis revisited Angiogenesis revisited - role and therapeutic potential of targeting endothelial metabolism role and therapeutic potential of targeting endothelial metabolism. J. Cell Sci. 127, 4331–4341 (2014).
  CAS PubMed Google Scholar
• Xu, Y. et al. Endothelial PFKFB3 plays a critical role in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 34, 1231–1239 (2014).
  CAS PubMed PubMed Central Google Scholar
• Wells, R. G. Tissue mechanics and fibrosis. Biochim. Biophys. Acta 1832, 884–890 (2013).
  CAS PubMed PubMed Central Google Scholar
• Home, P. D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373, 2125–2135 (2009).
  CAS PubMed Google Scholar
• Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005).
  CAS PubMed Google Scholar
• Chalasani, N. et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148, 1340–1352.e1347 (2015).
  PubMed Google Scholar
• Holoshitz, N., Alsheikh-Ali, A. A. & Karas, R. H. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am. J. Cardiol. 101, 95–97 (2008).
  CAS PubMed Google Scholar
• Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J. & Peters, J. M. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol. Sci. 90, 269–295 (2006).
  CAS PubMed Google Scholar
• Faghihzadeh, F., Adibi, P., Rafiei, R. & Hekmatdoost, A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr. Res. 34, 837–843 (2014).
  CAS PubMed Google Scholar
• Steneberg, P. et al. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight 3, 12 (2018).
  Google Scholar
• Liu, Y. et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 112, 1678–1687 (2003).
  CAS PubMed PubMed Central Google Scholar
• Erstad, D. J. et al. A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis. J. Hepatology 66, S165 (2017).
  Google Scholar
• Chen, H. et al. SAT-341-MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects. J. Hepatology 70, e789 (2019).
  Google Scholar
• Khalil, N. et al. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 53, 1800663 (2019). This study establishes the safety and efficacy of PBI-4050 as an antifibrotic therapy in patients with IPF.
  CAS PubMed PubMed Central Google Scholar
• Shi, J. et al. Discovery of potent and orally bioavailable dihydropyrazole GPR40 agonists. J. Med. Chem. 61, 681–694 (2018).
  CAS PubMed Google Scholar
• Sunil, V. et al. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacol. Toxicol. 15, 19 (2014).
  PubMed PubMed Central Google Scholar
• Bazydlo, K., Buda, P., Mach, M. & Dzida, R. Discovery of CPL207-280CA, an effective and safe GPR40 agonist for the treatment of type 2 diabetes. Diabetes 67, 1189 (2018).
  Google Scholar
• Takano, R. et al. Discovery of DS-1558: a potent and orally bioavailable gpr40 agonist. ACS Med. Chem. Lett. 6, 266–270 (2015).
  CAS PubMed PubMed Central Google Scholar
• Ruzehaji, N. et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann. Rheum. Dis. 75, 2175–2183 (2016).
  CAS PubMed Google Scholar
• Kim, S. G. et al. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLOS ONE 9, e92843 (2014).
  PubMed PubMed Central Google Scholar
• Jani, R. H. et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol. Ther. 16, 63–71 (2014).
  CAS PubMed PubMed Central Google Scholar
• Oruqaj, G. et al. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling. Proc. Natl Acad. Sci. USA 112, E2048–E2057 (2015).
  CAS PubMed PubMed Central Google Scholar
• Ishibashi, S. et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J. Clin. Lipidol. 12, 173–184 (2018).
  PubMed Google Scholar
• Wakida, Y., Suzuki, S., Nomura, H. & Isomura, T. Additional treatment with fenofibrate for patients treated with pitavastatin under ordinary medical practice for hypertriglyceridemia in japan (APPROACH-J study). Jpn Clin. Med. 2, 57–66 (2011).
  CAS PubMed PubMed Central Google Scholar
• Davidson, M. H. et al. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin. Ther. 31, 2824–2838 (2009).
  CAS PubMed Google Scholar
• Routh, R. E., Johnson, J. H. & McCarthy, K. J. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int. 61, 1365–1376 (2002).
  CAS PubMed Google Scholar
• Weigert, C., Brodbeck, K., Bierhaus, A., Häring, H. U. & Schleicher, E. D. c-Fos-driven transcriptional activation of transforming growth factor beta-1: inhibition of high glucose-induced promoter activity by thiazolidinediones. Biochem. Biophys. Res. Commun. 304, 301–307 (2003).
  CAS PubMed Google Scholar
• Burgess, H. A. et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 288, L1146–L1153 (2005).
  CAS PubMed Google Scholar
• McHutchison, J. et al. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology 138, 1365–1373 1373.e1-2 (2010).
  PubMed Google Scholar
• Bril, F. et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without Type 2 diabetes. Clin. Gastroenterol. Hepatol. 16, 558–566.e552 (2018).
  CAS PubMed Google Scholar
• Galli, A. et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122, 1924–1940 (2002).
  CAS PubMed Google Scholar